

1 Autoimmunity, Antibody Dependent COVID-19 Enhancement and Other Risks of SARS
2 CoV-2 Vaccination: Beneath the Tip of the Iceberg.

3 Mina T. Kelleni, MD, PhD

4 Pharmacology Department, College of Medicine, Minia University, Egypt

5 mina.kelleni@mu.edu.eg; drthabetpharm@yahoo.com

6 Mobile: +201200382422

7 <https://orcid.org/0000-0001-6290-6025>

8 Highlights

9 Some SARS CoV-2 vaccines have been investigated and all have not been fully approved.
10 SARS CoV-2 vaccines might induce autoimmunity that could be fatal.

11 SARS CoV-2 induced antibody dependent enhancement has not been excluded yet.

12 An informed personalized risk benefit ratio before receiving SARS CoV-2 vaccines must
13 be secured.


14 Abstract

15 mRNA based and adenovirus vectored vaccines, were first ever or first commercially ever
16 approved for the public, respectively. However, these new types possess a potential risk to
17 induce auto-immune diseases e.g., thrombocytopenia and some of these complications
18 might also reason for some of the post vaccination sudden death reports e.g., autoimmune
19 myocarditis and immune induced thrombosis and thromboembolism. Moreover, all SARS
20 CoV-2 types of vaccines, depending on the spike protein immunogenicity, especially the
21 conventional inactivated ones might increase the likelihood of COVID-19 severity upon
22 re-infection through antibody dependent enhancement which might reason for the recently
23 described abundance of hospital admissions within seven days of vaccination and might
24 also reason for some of the serious adverse effects encountered with administration of
25 convalescent plasma to COVID-19 patients. Furthermore, these vaccines might have
26 shared in development of the potentially more lethal SARS CoV-2 B.1.617 variants and

might lead to evolution of more virulent ones. Finally, we suggest that making these COVID-19 vaccines compulsory is a crime against humanity.

Keywords: COVID-19, SARS CoV-2, Oxford/AstraZeneca ChAdOx1 nCoV-19 vaccine, Johnson & Johnson Ad26.COV2-S vaccine, Pfizer-BioNTech BNT162b2 vaccine, Moderna mRNA-1273 vaccine, Autoimmune diseases, Antibody dependent enhancement, SARS CoV-2 B.1.617 variants, Vaccine passports.

Graphical abstract



Introduction

Safe COVID-19 vaccines are considered of utmost importance to stem SARS CoV-2 current pandemic¹. However, the unprecedented accelerated timelines to develop some of COVID-19 vaccines have necessitated a critical call for active pre- and post-licensure safety surveillance systems to properly investigate potential adverse effects or toxicities¹⁻³. Importantly, whether the incidence of SARS CoV-2 vaccine related serious adverse effects might be considered rare or less rare [https://www.smh.com.au/national/astrazeneca-advice-unlikely-to-change-despite-rate-of-rare-clotting-doubling-20210427-p57mq8.html] or very difficult to be prove causation⁴, the scientific community has an obligation to continue developing new standards for safety monitoring and most importantly the public has a moral and legal right to know the potential hazards of COVID-19 newly approved vaccines in order to freely decide whether or not to receive any after an informed personalized risk benefit ratio is provided. Notably, in a recent report, even the high risk groups to develop COVID-19 complications might eventually might not benefit from SARS CoV-2 vaccines as previously expected and repeatedly advertised and we consider this report [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/982499/S1208_CO-CIN_report_on_impact_of_vaccination_Apr_21.pdf?fbclid=IwAR1wKZUaG9UOgYMsvwbeQatY-aLG3eRz0mYFAMQxY5QF4xn3hlmtZxGWIV0] though considered of low evidence at least currently, a rare one as regards to its high scientific integrity among a flood of biased mostly funded trials and reports as we suggest.

Interestingly, autoimmunity developing due to similarities between viral and human proteins is one of the known sequelae of viral infections that include short term and sometimes permanent damage to the CNS⁵. However, this risk associated with COVID-19 vaccines especially the newly approved SARS CoV-2 ones is yet to be discovered. In this manuscript, we briefly discuss the potential autoimmune adverse effects of SARS CoV-2 nucleic acid-based vaccines; adenovirus vectored and mRNA vaccines. Furthermore, we also briefly discuss the potential risk to develop more severe COVID-19 upon SARS CoV-2 reinfection after vaccination as compared to the natural infection; a phenomenon called

antibody dependent disease enhancement and its potential association with adverse effects encountered while convalescent plasma was administered to COVID-19 patients. Finally, we illustrate, from our point of view, some of the higher risk groups to develop autoimmune disorders wishing they might consider a personalized risk benefit ratio, and measures that might decrease this potential. We wish to confirm that the public has a moral, legal, and constitutional right to know all the potential risks including the rarest ones to allow an informed personalized risk benefit ratio to be weighed and decided. This right should never be argued or suppressed as, unfortunately, it appeared as the case when a professional peer review for this and other related preprinted manuscripts has been previously denied by several well reputed medical journals.

Adenovirus vectored vaccines potential autoimmunity risk

Autoimmunity developing due to similarities between viral and human proteins is one of the known sequelae of viral infections that include short term and sometimes permanent damage to the CNS⁵. Moreover, an increased autoimmunity risk was hypothesized due to the inclusion of new adjuvants into the already approved licensed vaccines⁶. However, this risk associated with COVID-19 vaccines especially the newly approved SARS CoV-2 ones is yet to be discovered.

Notably, adenovirus vectored SARS CoV-2 vaccine has been first commercially approved to be used in humans in Russia which is currently undergoing a mass vaccination program. Moreover, on December 30, 2020, it has also been announced to be authorized for emergency supply in the UK followed by other countries.

Importantly, two adenovirus vectored SARS CoV-2 vaccine global phase III clinical trials were temporarily paused due to reports of serious adverse medical events of autoimmune and/or inflammatory complications including multiple sclerosis and transverse myelitis which were ultimately deemed to be unrelated to the SARS CoV-2 vaccine. Moreover, lack of transparency concerns have been raised as the involved companies declined the release of the thorough details of these serious adverse events claiming patients' privacy issues⁷⁻¹⁰ and a sharp criticism of the analysis of the results of one trial including a serious dose mistake, claimed later to be a beneficial mistake, that involved thousands of patients has also been raised¹¹. Importantly, supraphysiological expression levels of spike proteins in

some individuals who receive nucleic acid based vaccination might share in development of autoimmune reactions¹² and we suggest that a skewed immune virus spike protein-antibody complex might trigger and reason, at least partly, for this potential autoimmunity¹³ and we recommend that the dose of the nucleic acid based vaccines, if decided to be received, should be optimized to the lowest possible and preferably to be given once and potential tools to prevent such reactions should be further developed and tested.

mRNA vaccines potential autoimmunity risk

mRNA based vaccines, first approved in UK for COVID-19 as a first ever approval for this novel type of vaccination in a western country to be followed by USA, the European Medicines Agency as well as several countries worldwide, possess multiple theoretical and manufacturing advantages over traditional subunit, live attenuated and killed virus vaccines¹⁴⁻¹⁶. However, their remarkable high efficacy in SARS CoV-2 clinical trials contradicted the results of other previous clinical trials using mRNA vaccines to prevent H10N8, H7N9 influenza and rabies viruses which have been lower than what was expected when compared to those of their preclinical studies¹⁵. Moreover, though mRNA vaccines encoding HIV and CMV antigens elicited antigen-specific CD4+ and CD8+ T cell immune responses; no reduction in viral load was observed¹⁴.

Importantly, potential risks of mRNA, and saRNA, based vaccines include risk of autoimmunity due to development of autoreactive antibodies of any non-native nucleotides and delivery system components. Furthermore, the identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination was advised^{15,17,18}. Notably, other than the currently known potential risks of anaphylaxis or Bell's palsy (<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>), soon after mRNA based SARS CoV-2 vaccine approval, the Norwegian Medicines Agency is investigating the potential causation of Pfizer-BioNTech mRNA (BNT162b2) vaccine against Covid-19 and the death of 75-year-old and elder 33 recipients. Similarly, the Paul Ehrlich Institute in Germany has been reported to investigate 10 fatalities that occurred within four days of vaccination and whose age groups were not revealed to the public but described as previously seriously ill patients suffering from many underlying diseases¹⁹. Alarming, though attributing these fatalities to commonly encountered

adverse effects in the elderly is usually advocated, yet an otherwise healthy 56-year-old American obstetrician and gynecologist has developed autoimmune thrombocytopenia three days after receiving BNT162b2 vaccine and later he was deceased of brain hemorrhage as a complication to this autoimmune disease. Similarly, another American 60-year-old X-ray technologist was deceased four days after taking his second dose of the BNT162b2 vaccine, he complained of an acute abdominal pain and dyspnea and tested negative for COVID-19, later his condition deteriorated, was put into a medically induced coma and a ventilator and finally he suffered from severe hypotension before death. Other than overweight and hypertension, he has not complained of any concomitant disorder. Moreover, at least one participant in the clinical trials has suffered from cardiac arrest (<https://www.reuters.com/article/uk-factcheck-pfizer-health-concerns-idUSKBN28K2R6>) and an otherwise healthy 41-year-old Portuguese nurse was found dead two days after receiving BNT162b2 vaccine. Similarly, a frightening analysis has seriously doubted the integrity of the safety data reported by the Israeli ministry of health as regards to it adopted policy for mass vaccination with BNT162b2 vaccine [[http://www.nakim.org/israel-forums/viewtopic.php?t=270812&s=The uncovering of the vaccination data in Israel reveals a frightening picture&fbclid=IwAR3qTWwbnGVhmkhjOqDktSaYB_QAGTBkk1SETlrXS0GJvDOMMXl5W8qPjuA](http://www.nakim.org/israel-forums/viewtopic.php?t=270812&s=The_uncovering_of_the_vaccination_data_in_Israel_reveals_a_frightening_picture&fbclid=IwAR3qTWwbnGVhmkhjOqDktSaYB_QAGTBkk1SETlrXS0GJvDOMMXl5W8qPjuA)] and an informal weak criticism of this report has confirmed the validity of its statistics [<https://www.lesoleil.com/actualite/verification-faite/verification-faite-un-vaccin-qui-aggrave-les-symptomes-vraiment-653bb8c18253322defd076a115d8a83e>]. Additionally, another report claims that there is a post BNT162b2 mass vaccination increasing Israeli all-cause mortality with an observational “murky wave of heart attacks” as well as suggestions of intended official lack of transparency [https://swprs.org/israel-why-is-all-cause-mortality-increasing/?fbclid=IwAR0WX4OUR67KWZrxpVqBmV5Z_Xhl114cJv4wCqJo2BzF_Fd7kbnWXg6LHo4]. Interestingly, though the official statements denies a single post SARS CoV-2 vaccination mortality [<https://www.reuters.com/article/uk-factcheck-israel-idUSKBN2AA2TS>], unofficial reports strongly contradict this claim [<https://www.facebook.com/lindsayfoord/videos/10157458591032391>] and one might ask for independent international investigations for the best interests of transparency.

Adenovirus vectored and mRNA vaccines common autoimmune risks.

Importantly, immune thrombocytopenia was previously attributed to IgG opsonized dengue virus complexes bound to Fc receptors in platelets which were also suggested to play a central role in development of antibody dependent enhancement during dengue infection²⁰ and we suggest that the same mechanism might also apply to reason for the reported post BNT162b2 and Moderna mRNA-1273 SARS CoV-2 mRNA vaccination induced thrombocytopenia [<https://www.nytimes.com/2021/02/08/health/immune-thrombocytopenia-covid-vaccine-blood.html>] that also led the EMA to start a review of safety signal in patients who received any of BNT162b2, mRNA-1273 and Oxford/AstraZeneca (ChAdOx1 nCoV-19) (adenovirus vectored) vaccines [<https://www.reuters.com/article/brief-ema-reviews-safety-signal-of-immun-idUSFWN2LA0PH>]. Moreover, autoantibody induced thrombosis was previously described in another setting²¹ as well as other potential mechanisms for immunothrombosis²² and venous thromboembolism was shown to be consistently associated with autoimmune diseases²³ and we suggest that a dysregulated autoimmunity might be triggered in some individuals who received SARS CoV-2 vaccines leading to sudden death from thromboembolism though only ChAdOx1 nCoV-19 vaccine has been in focus because of multiple simultaneous fatality reports that led some European countries to halt its administration, at least temporarily, as becoming usual, while falsely claiming similar incidence in the general population [<https://www.dw.com/en/covid-several-european-countries-halt-use-of-astrazeneca-vaccine/a-56835406>] as the abstract facts refute this claim and declare that these vaccine related extremely serious adverse effects are more frequent than would be expected by chance [https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-19?utm_campaign=news_daily_2021-03-17&et rid=181260252&et_cid=3703486]. Importantly, the reported cerebral venous sinus thrombosis, encountered post ChAdOx1 nCoV-19 vaccination [<https://www1.racgp.org.au/newsgp/clinical/atagi-review-of-astrazeneca-covid-vaccines-what-gp>] was previously described with autoimmune thyroiditis/hypothyroidism²⁴ and its risk factors include the presence of autoantibodies like antiphospholipid and anticardiolipin antibodies²⁵ and fortunately some scientists from Norway and Germany have

independently confirmed the ability of ChAdOx1 nCoV-19 to trigger this autoimmune reaction [<https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-linked-to-astrazeneca-vaccine-11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b543rwBtiyImGT2Vf9RZeZu99w>] and later AstraZeneca was instructed to flag a possible thrombotic side-effect of ChAdOx1 nCoV-19 vaccine on labelling [<https://www.reuters.com/article/us-health-coronavirus-astrazeneca-statem/astrazeneca-to-flag-possible-blood-clot-side-effect-of-covid-19-vaccine-on-labelling-idUSKBN2BU2Z5>]. Recently, vaccine-induced immune thrombotic thrombocytopenia was coined to describe the pathogenesis of these cases²⁶.

Ironically, the same sequence of denial, investigations appears to occur with the Johnson & Johnson adenovirus vectored SARS CoV-2 Ad26.COV2-S vaccine and the FDA initially declared that currently no causal thrombosis relationship is found [<https://www.reuters.com/article/us-health-coronavirus-europe-vaccines/jj-covid-19-vaccine-under-eu-review-over-blood-clots-idUSKBN2BW2FI>], but fortunately a prompt vigilant decision of a temporary pause of Ad26.COV2-S vaccine until further evaluation was issued [<https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine>]. Notably, we have formally contacted the FDA before this pause and emailed a draft of this manuscript and later we urged it to respond like EMA and wisely they did [<https://edition.cnn.com/2021/04/23/health/johnson-vaccine-acip-recommendation/index.html>]. Most recently some European countries have fully suspended the use of ChAdOx1 nCoV-19 vaccine and even UK has restricted its use to people over 40 years old instead of those over 30 years old [<https://www.reuters.com/world/uk/uk-advises-under-40s-take-alternative-astrazeneca-covid-19-shot-2021-05-07/>] and analysis of its association with the autoimmune Guillain-Barré syndrome [<https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/>].

Unsurprisingly, British scientists have retaliated and recently exposed that post SARS CoV-2 vaccines thrombotic events are not limited to the cerebral vasculature as splanchnic

and portal vein thrombosis with similar case fatality rate (18.8% versus 20% of cerebral venous thrombosis) within two weeks post vaccination are more common with BNT162b2 and mRNA-1273 vaccines (44.9 per million versus 1.6 per million for their ChAdOx1 nCoV-19 vaccine) and they have mentioned that the incidence is much higher after COVID-19 but we suggest that their comparison is not out of bias especially when properly adjusted for the affected age and gender^{27,28} and one may wonder what else is hidden and when it will be exposed. Moreover, we would like to suggest that a fatal autoimmune myocarditis, which is known to be underdiagnosed, might also be responsible for some of the post SARS CoV-2 mRNA vaccination sudden death reports which are being attributed to other adverse effects which are not directly related to mRNA vaccine while they might be due to vaccine related myocarditis causing due to fatal arrhythmias, acute-onset heart failure with cardiogenic shock, pericardial effusion with cardiac tamponade^{29,30}. Importantly, a 19-year-old Israeli patient suffered from tachycardia, dyspnea, and angina like pain after receiving his second dose of BNT162b2 vaccine to be hospitalized five days later with a confirmed diagnosis of myocarditis. Importantly, since IL-6 has been suggested to play an integral role in the pathogenesis of clinical and experimental viral myocarditis^{31,32}, we would like to suggest that the potential clinical benefits of few days administration of NSAIDs with SARS CoV-2 vaccines³³ either concomitantly or on the day after both the first and second (if there is one) jabs might eventually exceed the inconclusive potential risk to lower the immune response developed from the vaccines³⁴. Recently and fortunately, EMA has begun an investigation to assess the association between SARS CoV-2 mRNA vaccines and myocarditis has started with the usual declaration that no indication at present that these cases were due to the vaccines [<https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/>].

Notably, supraphysiological expression levels of spike proteins in some individuals who receive nucleic acid based vaccination might share in development of autoimmune reactions and we suggest the dose of the nucleic acid based vaccines should be optimized to the lowest possible dose and potential tools to prevent such reactions should be further developed and tested¹². Moreover, an immunopathological phenomenon called antibody dependent enhancement that might cause COVID-19 enhancement, discussed later, should

be tested for a potential concomitant correlation. Some vaccines recipients who were previously primed by either SARS CoV-2 as silent infection or possibly through other commonly encountered corona viruses, might express an autoimmune lung reaction which was suggested to reason for COVID-19 pathogenesis^{5,35} and we suggest it might better suit COVID-19 complications whether or not linked to vaccination.

BNT162b2 vaccine potential extra risk

Importantly and unfortunately, the sequence used in BNT162b2 vaccine was suggested to induce misleading errors in translational decoding and protein synthesis that were hypothesized to produce serious long-term health damage including neurodegenerative diseases and multiple sclerosis³⁶. Furthermore, several adjuvants newly used in vaccines are known to trigger the innate and adaptive immune system with a theoretical, not confirmed, risk to induce autoimmune diseases⁶ and since most of the serious adverse effects and fatalities are reported with the BNT162b2 vaccine, there is a likelihood for at least a short-term potential hazard that might be a company specific, to be also fully investigated and compared as regards to sequence and used adjuvants it to its mRNA-1273 counterpart as an essential component of any investigation. Furthermore, we would like to recommend CDC to urgently change its neutral recommendation and to advice against administration of nucleic acid-based vaccines to persons complaining from autoimmune diseases [<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>]. Finally, we recommend consideration of an immediate reevaluation of the emergency approval granted by the FDA to BNT162b2 vaccine until full investigations of the claims against its design and its potential causation of some of the reported deaths are performed and discussed.

Antibody dependent COVID-19 enhancement potential risk: vaccines and convalescent plasma links

Importantly, an unexplored risk for all types of SARS CoV-2 vaccines, especially the inactivated ones, that aim to develop antibodies against its spike protein is an immunopathological well recognized phenomenon called antibody dependent enhancement which was reported and described with other respiratory and corona viruses including SARS CoV and MERS ^{5,37}. It was previously reported that in the presence of

vaccine-elicited antiviral antibodies, SARS-CoV displayed an altered tropism toward primary human immune cells which were otherwise refractory to the virus. Furthermore, vaccines developed against animal coronaviruses has demonstrated an immune enhancement of disease in vaccinated recipients³⁸. Importantly, individuals suffering from severe COVID-19 were suggested to be primed by one or more prior coronavirus exposures, and due to antigenic epitope heterogeneity, are experiencing the effects of ADE similar to that previously postulated with SARS CoV³⁹. Additionally, recurrent COVID-19 infection was described, in a significant minority due to a variable immune response, to be more severe and potentially fatal⁴⁰. Interestingly, SARS CoV-2 vaccines were also suggested to possess the same risk and a modification of their design was suggested to lower the potential risk⁵. Notably, a higher antibody titre against SARS-CoV-2 being was associated with more severe disease and suggested to be linked to ADE as one possible probability that was not excluded by the other suggested mechanisms. Moreover, several studies in murine and non-human primate models for SARS-CoV vaccines showed enhanced immunopathology, enhanced respiratory disease⁴¹ or skewing immunological or inflammation-resolving response^{37,42,43} on challenge with SARS CoV after immunization and thus the benefit of using SARS-CoV vaccine in humans was doubted⁴⁴ and a very interesting commentary that unfortunately has been unnoticed possibly because of multiple prior rejections at more visible journals has tested the outcomes of SARS CoV-2 infection in 33 African green monkeys which were vaccinated with mRNA SARS CoV-2 vaccines and ARDS has developed in one⁴⁵. Accordingly, we disagree with Fu et al.⁴⁶ in their suggestion that an early, sub-optimal neutralizing antibody activity reasons for ADE responsible for the severe SARS CoV induced pulmonary disease and with Lee et al.⁴¹ and in their suggestion, basing on interpretations of some murine models findings, that SARS CoV-2 vaccines that elicit high neutralizing antibody titres have a minimal risk of ADE which is supported by a preprinted study that used a SARS CoV-2 murine model⁴⁷ to be noted that neutralizing antibodies are described to induce ADE^{42,48} and a SARS CoV-2 DNA study that has been performed in non-human primates and frequently cited to acquit COVID-19 from ADE potential has clearly stated that it was not designed to examine safety issues. Furthermore, it recommended future studies to specifically address the probability of enhanced respiratory disease due to ADE implying that their favorable

impression should never be cited as potentially conclusive⁴⁹. Importantly, another argument that is used as a principle to refute or underestimate COVID-19 ADE risk is that antibodies can have very different properties in animals compared to those in the human host, because of altered functional species-specific interactions between the antibody and immune cells⁵⁰ should be used likewise in favor of the contradictory perspective as explained, further we suggest that results coming from non-corona viruses should not be considered of much significant value when trying to interpret the potential risk of ADE in COVID-19. Moreover, we suggest that while COVID-19 does not worsen after treatment with plasma from convalescent patients⁵⁰, it should also be considered irrelevant in a context that underestimate COVID-19 potential ADE risk for two reasons; the first is the timing as these antibodies are being administered to combat an undergoing infection and the other is that in fact these antibodies might actually have worsened COVID-19 if proper validation of cardiac events was conducted and thus an early ADE should not be excluded⁵¹. Interestingly, abundance of hospital admissions was described within seven days post SARS CoV-2 vaccination and it was hypothesized that this might occur with recently asymptomatic SARS CoV-2 infected patients who received the vaccines [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/982499/S1208_CO-CIN_report_on_impact_of_vaccination_Apr_21.pdf?fbclid=IwAR1wKZUaG9UOgYMsvwbeQatY-aLG3eRz0mYFAMQxY5QF4xn3hlmtZxGWIV0] and we recommend investigating this hypothesis as it might eventually appear as a mild form of ADE. Alarming, unlike the one year spent to develop a vaccine for SARS CoV-2 (a single-stranded RNA virus), the journey to develop RSV (another enveloped non-segmented single stranded RNA virus) vaccine took more than 60 years and has not ended yet. More alarmingly, 80% of young infants previously vaccinated with inactivated RSV who have been subsequently infected with wild RSV experienced enhanced respiratory disease that required hospitalization and two died and ⁵² and an atypical measles illness accompanied by peripheral edema and pneumonia occurred in ten children who had received inactivated measles (a third enveloped non-segmented single stranded RNA virus) vaccine five to six years earlier and significant pleural effusions were noted in three of them⁵³. Importantly, we wish to strongly recommend against any suggested administration of SARS CoV-2

vaccines to children, especially the inactivated ones. Moreover, we confirm our recommendation using the lowest possible vaccination dose optimized to produce high-affinity anti-SARS CoV-2 IgG as this might be our route to decrease this and other potential likelihoods. Additionally, we reconfirm the need for developing suggested neutralizing nanobodies as well as new immunofocusing vaccines basing on the spike, N or other potential SARS CoV-2 immunological targets³⁷. Finally, though reports of SARS CoV-2 infection early after vaccination have not reported ADE⁵⁴, yet the recent terrible surge of COVID-19 mortality in India should be further investigated whether SARS CoV-2 B.1.617 variants are the sole culprit and whether the enthusiastic Indian vaccination program might helped in the emergence of these potentially more lethal variants⁵⁵ and the timing of infection might also play a factor in development of ADE as well as some individualized immune-genetic factors and thus, from our point of view, an advice for close and vigilant follow up should not be ignored and any report of such adverse effect should not be underestimated.

Who are the higher-risk groups, and could we lower their potential risk?

Notably, we would like to explore some groups of individuals who are potentially more vulnerable to autoimmune diseases, aiming to recommend a personalized risk benefit ratio to be considered before a decision to be immunized by adenovirus and RNA based SARS CoV-2 vaccine until encouraging post marketing safety data are revealed for all SARS CoV-2 types of vaccines. The first higher-risk group are female⁵⁶ and this is a non-modifiable risk factor and the second are smokers; cigarette smoke has been reported to lead to an enhanced risk of inflammatory and autoimmune diseases⁵⁷. Smokers are more likely to develop critical COVID-19 requiring mechanical ventilation⁵⁸ that might lead to a higher mortality rate^{59,60}. Interestingly, alarms about the danger of misreading non-significant or inconclusive frequentist results containing several possible biases of a contradictory hypotheses have been raised^{61,62}.

Two other important groups that might be closely monitored include obese and diabetic individuals; obesity was suggested to be a major environmental factor contributing to the onset and progression of autoimmune diseases⁶³ and a concomitant autoimmune disease was encountered as 1 in 4 of 179,248 people diagnosed with type 1 diabetes⁶⁴. Notably, a

meta-analysis has showed diabetes, but not obesity, to be linked to a higher COVID-19 mortality⁶⁵. However, increasing risks of COVID-19 hospital death were noticed to be associated with increasing levels of obesity (BMI >40 fully adjusted HR 2.27, 95% CI 1.99-2.58)⁶⁶.

Interestingly, quitting smoking at diagnosis was recently shown to decrease the risk of death in cancer patients⁶⁷, and quitting smoking was suggested to alleviate its impact in patients with pneumonia and other COVID-19 associated infections^{60,62,68}, thus a beneficial advice to quit smoking together with another to lose overweight and to control the blood glucose levels might also help to lower the chances of SARS CoV-2 adenovirus and RNA-based vaccine potential autoimmunity in those individuals. Most importantly, we would like to stress the utmost importance to remind the participants to report all experienced adverse effects to a well-prepared post marketing surveillance system. Further, the search to improve methods that help to develop nucleic acid-based vaccines with minimal autoimmune potential risk should continue and until more reassuring post marketing safety data are released, we recommend considering an individualized risk benefit ratio especially for those higher risk groups of patients.

Conclusion

In conclusion, we totally condemn, from a medical point of view, any national policy that necessitates these experimental vaccines and we also condemn the European Court of Human Rights shameful ruling that compulsory vaccination would not contravene human rights law [<https://www.dw.com/en/echr-rules-obligatory-vaccination-may-be-necessary/a-57128443>]. Moreover, though “experts” finally admit that their claimed vaccine induced herd immunity is very unlikely⁶⁹ or almost impossible [<https://www.nytimes.com/2021/05/03/health/covid-herd-immunity-vaccine.html>], they continue to make it almost compulsory and advocate for vaccine passports. Alarming, we also condemn the trials made by some pharmaceutical companies to test those vaccines in children as well as their attempt to seek clearance of usage in children aged two years and above [https://www.nytimes.com/2021/05/04/health/pfizer-vaccine-children-approval.html?action=click&block=associated_collection_recirc&impression_id=d81bf912-ad21-11eb-879f-e72e2db5680e&index=2&pgtype=Article®ion=footer] as other

than the discovered potential short term complications, long term ones are not excluded as well ³⁶. Notably, we are regretful that many “honorable” journals, including one affiliated to the CDC, have refused to peer review this manuscript though a draft was submitted to some several months ago and before the appearance of mortalities attributed to those vaccines. Ironically, nothing is comparable to this misfortunate dishonorable academic misconduct except the intended one year persistent denial, by dozens of similarly “reputable” journals to fairly review our immunomodulatory protocol that provides a safe, inexpensive cure to COVID-19 and even when it was accepted after peer review, some have intervened to remove it from publication⁷⁰. We repeat urging the CDC to consider a change to its current recommendation to advise against use of nucleic acid based vaccination for COVID-19 patients complaining of autoimmune diseases and we suggest that FDA should investigate a potential extra risk that might be associated with BNT162b2 vaccine and calling for an independent re-evaluation of the post vaccination situation in Israel and we totally agreed with the EMA and FDA decisions to reevaluate the safety of ChAdOx1 nCoV-19 and Ad26.COV2-S vaccines, respectively. Furthermore, that risk benefit ratio from administering convalescent plasma to COVID-19 patients might be outbalanced due to potential early ADE. Moreover, a strict system for post vaccination surveillance must be secured to report any encountered serious adverse effect especially for those who would be reinfected with SARS CoV-2 despite vaccination. Additionally, the techniques used in development of all types of SARS CoV-2 vaccines, especially the newly emergency approved ones, should focus on innovative methods to decrease their potential autoimmunity and antibody dependent disease enhancement. Finally, in all cases we believe that a more careful consideration of these potential hazards must have been thoroughly discussed and/or refuted before a mass vaccination approval was granted as the public, which has been repeatedly denied a constitutional right to know, will not accept to prevent a minority of unaware recipients who experienced the presented adverse effects from their legal right to know first then decide, no matter if the adverse effects are rare as frequently claimed or not to the same extent that we will not withstand any political or economic gains that might have induced or would induce a man-made Hades currently or in the future and we wish to remind all stake-holders that no prior agreements will, ever, secure impunity.

Acknowledgments

This work is dedicated to Egypt; a country that I am proud to be one of its citizens, Africa; the continent that has suffered oppression for centuries and especially to my beloved mother to whom I owe my endurance and faith. The author would also like to sincerely thank Dr. James Lyons-Weiler (The Institute for Pure and Applied Knowledge; US) who after reading a preprint has generously emailed three valuable immunology related references that have enriched this and other manuscripts and I am also very grateful to Dr. Viera Malachovska, Ing, PhD a Slovakian scientist who has generously emailed precious links that discusses the safety concerns related to the BNT162b2 vaccine in Israel. I am also very much indebted to the precious feedback that has reached me from several individuals from many countries who have generously shared their reasonable doubt, fear and hopes after reading a preprint of this manuscript.

Funding

None

Conflict of interest

The author declares that he has no conflict of interest.

References

1. Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. *Vaccine* 2020;38:6194-8.
2. Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. *Drug Safety* 2020.
3. Shakir S, Lane S, Davies M. How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine. *Drug Safety* 2021;44:1-5.
4. Heidi Ledford. US authorization of first COVID vaccine marks new phase in safety monitoring. *Nature*, 2020, December 12;588:377-8.
5. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. *Journal of Translational Autoimmunity* 2020;3:100051.
6. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. *Immunity* 2010;33:492-503.
7. AstraZeneca pauses coronavirus vaccine trial as participant illness investigated. 2020, September 09. at <https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-pauses-coronavirus-vaccine-trial-rollout-doubts-dent-shares-idUSKBN26017L>.)

8. Covid-19 vaccine trials from AstraZeneca, Johnson & Johnson to restart. 2020, October 23. at <https://www.statnews.com/2020/10/23/covid-19-vaccine-trials-from-astrazeneca-johnson-johnson-to-restart/>.)
9. Ledford SMH. COVID-vaccine results are on the way — and scientists' concerns are growing. Nature 2020, September 25.
10. J&J pauses COVID-19 vaccine trials due to unexplained illness in participant. 2020, October 13. at <https://www.reuters.com/article/uk-health-coronavirus-johnson-johnson/jj-pauses-covid-19-vaccine-trials-due-to-unexplained-illness-in-participant-idUKKBN26Y02L>.)
11. After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine. 2020, November 25. at <https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html>.)
12. Wagner TE, Becraft JR, Bodner K, et al. Small-molecule-based regulation of RNA-delivered circuits in mammalian cells. Nature Chemical Biology 2018;14:1043-50.
13. Wen Y-M, Mu L, Shi Y. Immunoregulatory functions of immune complexes in vaccine and therapy. EMBO Mol Med 2016;8:1120-33.
14. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines for Infectious Diseases. Frontiers in Immunology 2019;10.
15. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery 2018;17:261-79.
16. Andries O, Kitada T, Bodner K, Sanders NN, Weiss R. Synthetic biology devices and circuits for RNA-based 'smart vaccines': a propositional review. Expert Review of Vaccines 2015;14:313-31.
17. Wang F, Kream RM, Stefano GB. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Med Sci Monit 2020;26:e924700-e.
18. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Therapy 2020.
19. NTV. Zusammenhang unwahrscheinlich: Institut prüft zehn Todesfälle nach Impfung [German]. 2021, January 14.
20. Guo L, Rondina MT. The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases. Front Immunol 2019;10:2204.
21. Hoffman M, Monroe DM, Roubey RA. Links between the immune and coagulation systems: how do "antiphospholipid antibodies" cause thrombosis? Immunol Res 2000;22:191-7.
22. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Reviews Immunology 2013;13:34-45.
23. Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides. Vascular Medicine 2015;20:369-76.
24. Aggarwal S, Sharma N. Cerebral venous sinus thrombosis with autoimmune thyroiditis. Indian J Endocrinol Metab 2013;17:S176-S7.
25. Carhuapoma Juan R, Mitsias P, Levine Steven R. Cerebral Venous Thrombosis and Anticardiolipin Antibodies. Stroke 1997;28:2363-9.
26. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine 2021.
27. See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA 2021.
28. Maxime Taquet MH, John R Geddes, Sierra Luciano, Paul J Harrison. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a

517 comparison with 489,871 people receiving a COVID-19 mRNA vaccine. OSFPREPRINTS (Preprint)
518 2021.

519 29. Bracamonte-Baran W, Čiháková D. Cardiac Autoimmunity: Myocarditis. *Adv Exp Med*
520 *Biol* 2017;1003:187-221.

521 30. Khalil A, Naneishvili T, Prasad N, Glancy J. SARS-CoV-2 myocarditis: what physicians need
522 to know. *BMJ Evidence-Based Medicine* 2021;bmjebm-2020-111527.

523 31. Esfandiarei M, McManus BM. Molecular Biology and Pathogenesis of Viral Myocarditis.
524 *Annual Review of Pathology: Mechanisms of Disease* 2008;3:127-55.

525 32. Savvatis K, Müller I, Fröhlich M, et al. Interleukin-6 receptor inhibition modulates the
526 immune reaction and restores titin phosphorylation in experimental myocarditis. *Basic Research*
527 *in Cardiology* 2014;109:449.

528 33. Kelleni MT. NSAIDs/Nitazoxanide/Azithromycin Repurposed for COVID-19: Potential
529 Mitigation of the Cytokine Storm Interleukin-6 Amplifier via Immunomodulatory Effects.
530 *Authorea (Preprint)*, 2021. DOI: 10.22541/au.162126674.45214133/v1

531 34. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to
532 vaccination. *Human vaccines & immunotherapeutics* 2016;12:2391-402.

533 35. Karaderi T, Bareke H, Kunter I, et al. Host Genetics at the Intersection of Autoimmunity
534 and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity. *Front Immunol* 2020;11.

535 36. Kira Smith. BNT162b2 Vaccine: Possible Codons Misreading, Errors in Protein Synthesis
536 and Alternative Splicing's Anomalies. *Journal of Antivirals & Antiretrovirals* 2021;13.

537 37. Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent
538 enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the
539 development of vaccines and immunotherapies to counter COVID-19. *Human Vaccines &*
540 *Immunotherapeutics* 2020;16:3055-60.

541 38. Yip MS, Leung NHL, Cheung CY, et al. Antibody-dependent infection of human
542 macrophages by severe acute respiratory syndrome coronavirus. *Virol J* 2014;11:82-.

543 39. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect*
544 2020;22:72-3.

545 40. Adrielle dos Santos L, Filho PGdG, Silva AMF, et al. Recurrent COVID-19 including
546 evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. *Journal of*
547 *Infection*.

548 41. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and
549 SARS-CoV-2 vaccines and therapies. *Nature Microbiology* 2020;5:1185-91.

550 42. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing
551 macrophage responses during acute SARS-CoV infection. *JCI Insight* 2019;4:e123158.

552 43. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus
553 vaccines leads to pulmonary immunopathology on challenge with the SARS virus. *PLoS One*
554 2012;7:e35421.

555 44. Yip MS, Cheung CY, Li PH, Bruzzone R, Peiris JSM, Jaume M. Investigation of Antibody-
556 Dependent Enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis of
557 SARS. *BMC Proceedings* 2011;5:P80.

558 45. Farshi E. Cytokine Storm Response to COVID-19 Vaccinations. *Journal of Cytokine*
559 *Biology* 2020;5: 1000125

560 46. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses:
561 From Mechanisms to Potential Therapeutic Tools. *Virologica Sinica* 2020;35:266-71.

47. Quinlan BD, Mou H, Zhang L, et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. *bioRxiv* 2020:2020.04.10.036418.
48. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. *Nat Rev Immunol* 2020;20:339-41.
49. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* 2020;369:806-11.
50. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature* 2020;584:353-63.
51. Pathak EB. Convalescent plasma is ineffective for covid-19. *BMJ* 2020;371:m4072.
52. Mejias A, Rodríguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. *Annals of Allergy, Asthma & Immunology* 2020;125:36-46.
53. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered Reactivity to Measles Virus: Atypical Measles in Children Previously Immunized With Inactivated Measles Virus Vaccines. *JAMA* 1967;202:1075-80.
54. Amit S BS, Biber A, Grinberg A, Leshem E, Regev-Yochay G. . Post-vaccination COVID-19 among healthcare workers, Israel. *Emerg Infect Dis* 2021.
55. Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for concern? *The Lancet Respiratory Medicine* 2021;9:333-5.
56. Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. *Cureus* 2020;12:e8094-e.
57. Hussain MS, Tripathi V. Smoking under hypoxic conditions: a potent environmental risk factor for inflammatory and autoimmune diseases. *Mil Med Res* 2018;5:11.
58. Adrish M, Chilimuri S, Mantri N, et al. Association of smoking status with outcomes in hospitalised patients with COVID-19. *BMJ Open Respir Res* 2020;7.
59. Jimenez-Ruiz CA, Lopez-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, de Granda-Orive JI. COVID-19 and Smoking: A Systematic Review and Meta-Analysis of the Evidence. *Arch Bronconeumol* 2020.
60. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: A systematic review and meta-analysis. *medRxiv* 2020.
61. Usman MS, Siddiqi TJ, Khan MS, et al. Is there a smoker's paradox in COVID-19? *BMJ Evidence-Based Medicine* 2020:bmjebm-2020-111492.
62. Carmona-Bayonas A, Jimenez-Fonseca P, Sánchez Arraez Á, Álvarez Manceñido F, Castañón E. Does active smoking worsen Covid-19? *Eur J Intern Med* 2020;77:129-31.
63. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. *Autoimmun Rev* 2014;13:981-1000.
64. Rogers MAM, Wei MY, Kim C, Lee JM. Sex Differences in Autoimmune Multimorbidity in Type 1 Diabetes Mellitus and the Risk of Cardiovascular and Renal Disease: A Longitudinal Study in the United States, 2001-2017. *J Womens Health (Larchmt)* 2020;29:511-9.
65. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. *European Journal of Clinical Investigation* 2020;50:e13362.
66. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv* 2020:2020.05.06.20092999.
67. Yang S, Liu T, Liang G. The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi-omics data. *Mol Oncol* 2020.

- 608 68. Coronavirus Disease 2019 (COVID-19): People with Certain Medical Conditions. 2020,
609 November 02. at [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking)
610 [with-medical-conditions.html#smoking.](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking))
- 611 69. Grant A, Hunter PR. Immunisation, asymptomatic infection, herd immunity and the new
612 variants of COVID 19. medRxiv 2021:2021.01.16.21249946.
- 613 70. Kelleni MT. NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in
614 Adults, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A
615 Prospective Observational Study and Case-Series. Authorea (Preprint) 2021. DOI:
616 10.22541/au.162126601.15715282/v1